Bristol-myers Squibb Compnay

Yueming Qian

Zhengjian Li

Ying Jing

Xuankuo Xu

Chao Huang

Zhiqiang Chen

Zhijun Tan

Sarwat Khattak

Sarwat F Khattak

In certain embodiments, the disclosure provides an IgG4 antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises: (a) a modified IgG4 CH1 region having a substitution of the lysine residue at position 196; or (b) a modified IgG4 hinge region having a substitution of the serine residue at position 217, the glycine residue at position 220, the proline residue at position 224 or the proline residue at position 225. Preferably, the IgG4 antibody further comprises a substitution of the serine residue at position 228 in the heavy chain hinge region.

Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties

The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise the addition of glucocorticoid compound during the culturing period. The addition of glucocorticoid compound sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein.

Mammalian cell culture processes for protein production

The present invention provides methods for reducing glycoprotein aggregation by optimizing the number of O-linked glycosylation sites.

Methods for reducing glycoprotein aggregation

Growing community of inventors

Pepperell, MA, United States of America

Yueming Qian